1 Genetics identifies obesity as a shared risk factor for co-occurring

2 multiple long-term conditions.

3 Short title: Genetics pinpoints obesity as a shared risk factor between diseases

- 4 Ninon Mounier¹, Bethany Voller¹, Jane AH Masoli^{1,2}, João Delgado¹, Frank Dudbridge³, Luke C
- 5 Pilling ¹, Timothy M Frayling ^{1,4}, Jack Bowden ^{1,5}, on behalf of the GEMINI Consortium
- 6

7 Affiliations

8	1.	Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences,						
9		University of Exeter, UK						
10	2.	Royal Devon University Healthcare NHS Foundation Trust, Barrack Road, Exeter, EX2 5DW, UK						
11	3.	Department of Population Health Sciences, University of Leicester, UK						
12	4.	Department of Genetic Medicine and Development, Faculty of Medicine, 1 rue Michel-						
13		Servet, CH-1211 Genève 4, Switzerland						
14	5.	Novo Nordisk Research Centre, Roosevelt Drive, Headington, Oxford, UK						
15								
16	Corresponding author							
17	Prof Jack Bowden (J.Bowden2@exeter.ac.uk)							
18								

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

21 <u>Background:</u> Multimorbidity, the co-occurrence of multiple long-term conditions (LTCs), is an 22 increasingly important clinical problem, but often little is known about the underlying causes. 23 Observational studies are highly susceptible to confounding and bias, and patients with multiple LTCs 24 are usually excluded from randomised controlled trials. We investigate the role of a potentially critical 25 multimorbidity risk factor, obesity, as measured by body mass index (BMI), in explaining shared 26 genetics amongst 71 common LTCs.

27

Methods and Findings: In a population of northern Europeans, we estimated unadjusted pairwise 28 29 genetic correlation, \hat{r}_{q} , between LTCs and partial genetic correlations after adjustment for the genetics 30 of BMI, $\hat{r}_{a|BMI}$. We compared these correlations using a bespoke block-jackknife approach to assess whether differences between the estimates were statistically meaningful. We then used multiple 31 32 causal inference methods to confirm that BMI causally affects not only individual LTCs, but also their 33 co-occurrence. Finally, we attempted to quantify the population-level impact of intervening and 34 lowering BMI on the prevalence of 15 key common multimorbid LTC pairs. Our results showed 35 evidence that BMI partially explains some of the shared genetics for 740 LTC-pairs (30% of all pairs considered). For a further 161 LTC-pairs, the genetic similarity between the LTCs was entirely 36 37 accounted for by BMI genetics. This list included diabetes and osteoarthritis: $\hat{r}_g = 0.221$ (SE = 0.021); $\hat{r}_{g|BMI} = -0.019$ (SE = 0.030), as well as those involving LTCs from the same broad family, 38 or `domain', such as gout and osteoarthritis: $\hat{r}_g = 0.192 (SE = 0.023)$; $\hat{r}_{g|BMI} = 0.019 (SE =$ 39 40 0.029). Causal inference methods confirmed that higher BMI acts as a common risk factor for a subset of these pairs, and therefore BMI-lowering interventions would reduce the prevalence of these pairs 41 42 of LTCs. For example, we estimated that a 1 standard deviation or 4.5 unit decrease in BMI would result in 17 fewer people with both chronic kidney disease and osteoarthritis per 1000 who currently 43 44 have both LTCs.

45

46 <u>**Conclusions:**</u> Our genetics-centred approach shows that obesity is an important mechanistic cause of 47 many shared long-term conditions. We identify LTC pairs for which obesity is the predominating shared 48 risk factor, and cases where it is one of the several shared risk factors involved. Our method for 49 calculating full and partial genetic correlations is published as an R package {*partialLDSC*} for use by 50 the research community.

51

52 Key words

53 Multiple long term conditions (MLTC); genetics; obesity; genetic correlation.

54 Introduction

55 Multimorbidity, defined as the coexistence of two or more long-term conditions (LTCs), is an important 56 public health challenge. The prevalence of multimorbidity differs across geographic regions, age 57 groups and between genders. It is also higher in more deprived individuals and is often associated with 58 lower quality of life and increased healthcare costs [1]. Many observational studies have focused on 59 defining and measuring multimorbidity [2,3]. However, disparate definitions have led to variations in 60 its characterisation [4]. For example, a thorough definition of chronicity and a list of chronic LTCs have been proposed by [5] and new approaches to cluster LTCs and identify patterns of multimorbidity have 61 62 been developed [6,7]. These approaches have limitations, as they often involve single datasets and 63 modalities, and cluster identification might differ depending on the algorithm [8].

64 Investigating the role of common epidemiological risk factors for multimorbidity is vitally important, as it can provide a better understanding of the mechanisms underlying the co-occurrence of LTCs and 65 66 help to develop efficient prevention strategies. For example, using observational data to study the relationship between socio-economic status and multimorbidity, it has been shown that lower 67 68 education level and higher deprivation were associated with increasing risk of multimorbidity [9]. A 69 large multi-cohort prospective study provided evidence of associations between obesity and a wide 70 range of LTCs, as well as with the number of LTCs developed, highlighting the potentially important 71 role of obesity in multimorbidity [10].

72 We have previously assessed the genetic similarity between 2546 pairs of LTCs [11], allowing us to re-73 examine associations from observational epidemiology. Using genetic predictors of a trait, rather than 74 observational measures, reduces the impact of inherent issues such as confounding, measurement 75 error and reverse causation [12]. These issues are particularly problematic for studies of 76 multimorbidity. Over the last decade, genetic approaches have also greatly benefited from the increase 77 in sample sizes, and methods that enable data from more than one cohort to be incorporated into the 78 analysis, enabling researchers to work with data linking tens of thousands of cases for common LTCs 79 from a large range of health exposures. This genetics-centred approach has been used to estimate the 80 costs of obesity on healthcare systems [13]. Our previous work showed evidence of widespread 81 genetic correlation across LTCs, with obesity being highly genetically correlated with a broad range of 82 LTCs [11]. Depending on context, obesity can be considered a risk factor for multiple LTCs or an LTC in 83 its own right. In this work, we focus on using statistical genetics methods to quantify the role of obesity as a common risk factor for multimorbidity. 84

Genetic correlation is driven by pleiotropy, when a genetic locus affects several traits, and can reflect
 different scenarios: a direct relationship between the two traits (vertical pleiotropy – when the two

traits are part of a causal cascade), a common biological process or the effect of a common risk factor
on both traits (horizontal pleiotropy – when the two traits have no direct effect on each other) [14]
(Supplementary Figure 1). Often, genetic correlations are driven by a combination of both vertical and
horizontal pleiotropy [15]. We propose an approach to help differentiate these mechanisms in
multimorbidity, focussing on obesity as a well-known risk factor for several long-term conditions [16].
We chose the most common, general clinical measure of obesity for this investigation: body mass index
(BMI).

We use data from the GEMINI collaborative for 71 long-term common LTCs comprising 2485 distinct pairs. We propose an approach to compare pairwise unadjusted genetic correlations to partial genetic correlations that accounts for BMI genetics, formally testing whether BMI explains a portion of the genetic correlation for a given LTC pair. We also applied causal inference methods to elucidate the causal (biological) mechanisms through which BMI affects the genetic correlation between LTCs, quantifying its pivotal role as a common risk factor in multimorbidity.

100 Methods

101 - Data resources

102 We used GWAS summary statistics, derived from individuals of European descent, for 71 common and 103 heritable LTCs, encompassing 13 distinct disease domains, grouped according to the International 104 Classification of Disease (ICD): such as cardiovascular or respiratory domains [17]. These GWAS data 105 are described in detail in [11]; relevant diagnostic and analytical code is available on the project GitHub 106 pages [https://github.com/GEMINI-multimorbidity]. LTCs were defined by adapting existing diagnostic 107 code lists with input from clinical experts. LTCs were selected for genetic analyses if reaching a 108 prevalence greater than 0.5% in people over 65 in each of two large population-based cohorts in the 109 UK and Spain [18,19]. Heritability measures the proportion of phenotypic variance explained by 110 genetics. We estimated this in UK Biobank [20] to identify a subset of LTCs with a genetic basis. Finally, 111 for each condition, we used the largest sample size available by combining GWAS data from up to three 112 sources: UK Biobank, FinnGen, and condition specific consortium data (details available in Supplementary Table 1). For many of these LTCs, the meta-analysed data used represents the largest 113 114 sample size used to date. We refer to these meta-analysed GWAS summary statistics as "GEMINI 115 summary statistics" for the rest of the paper.

We also used two different sets of GWAS summary statistics for BMI. First, we used the largest data to date ($N \approx 700,000$), combining results from the GIANT Consortium and UK Biobank [21], to estimate partial genetic correlations. We also used earlier results from the GIANT Consortium ($N \approx 340,000$ minimal overlap with the GEMINI summary statistics) [22], to perform causal inference analyses, after ensuring that the partial genetic correlations results were consistent with the ones obtained using the larger dataset.

The GWAS summary statistics for the 71 LTCs, as well as BMI, were pre-processed using the munging function from the LD-score regression (LDSC) [23] and for all LDSC analyses we used LD-scores estimated from the 1000G EUR reference panel.

125 - Covariance and correlation

126 Covariance measures the extent to which the observed value of one quantity predicts the value of 127 another quantity. For example, in the case of two such quantities – osteoarthritis (OA) and type 2 128 diabetes (T2D) diagnoses in a study population - a positive covariance would indicate that having T2D 129 increases the probability of having OA. *Correlation* is simply a scaled version of covariance that lies 130 between -1 and 1. If all individuals in a population with T2D also have OA, the two would have a

correlation of 1. If all individuals in a population with T2D do not have OA, the two would have acorrelation of -1.

133 - Partial genetic covariance and correlation

In this paper we extensively study the genetic covariance and correlation between two LTCs. That is,
the degree to which genetic variants that predict one LTC also predict the other LTC. Furthermore, we
focus on understanding how the genetic covariance between two LTCs changes when we remove the
genetic effects of a common risk factor.

Using the Schur complement, the partial (or `adjusted') genetic covariance between LTCs k and l($\hat{\rho}_{g\{k,l\mid x\}}$), which corresponds to their genetic covariance while holding the genetic effects of the trait 40 x (in our case, BMI) constant, can be defined as follows:

$$\hat{\rho}_{g\{k,l\mid x\}} = \hat{\rho}_{g\{k,l\}} - \frac{\hat{\rho}_{g\{k,x\}} * \hat{\rho}_{g\{x,l\}}}{\hat{h}_{\{x\}}^2}, \tag{1}$$

where

 $\hat{\rho}_{g\{k,l\}}$ is the genetic covariance between condition l and k, $\hat{\rho}_{g\{k,x\}}$ is the genetic covariance between condition k and trait x, $\hat{\rho}_{g\{x,l\}}$ is the genetic covariance between trait x and condition l, $\hat{h}_{\{x\}}^2$ is the heritability estimate for trait x.

141

Genetic covariance and heritability estimates were obtained from GWAS summary statistics usingcross-trait LD Score regression (LDSC), as previously described by [24].

144 Similarly, the partial heritability for LTCs k and $l(\hat{h}_{\{k|x\}}^2 \text{ and } \hat{h}_{\{l|x\}}^2, \text{ respectively})$ can be estimated:

$$\hat{h}^{2}_{\{k \mid x\}} = \hat{h}^{2}_{\{k\}} - \frac{\hat{\rho}_{g\{k,x\}} * \hat{\rho}_{g\{x,k\}}}{\hat{h}^{2}_{\{x\}}},$$

$$\hat{h}^{2}_{\{l \mid x\}} = \hat{h}^{2}_{\{l\}} - \frac{\hat{\rho}_{g\{l,x\}} * \hat{\rho}_{g\{x,l\}}}{\hat{h}^{2}_{\{x\}}},$$
(1)

where $\hat{h}^2_{\{k\}}$ is the heritability estimate for condition k,

 $\hat{h}^2_{\{l\}}$ is the heritability estimate for condition *l*.

145

Finally, the (unadjusted) genetic correlation $(\hat{r}_{g\{k,l\}})$ and the partial genetic correlation $(\hat{r}_{g\{k,l\mid x\}})$ between LTCs k and l can be derived:

$$\hat{r}_{g\{k,l\}} = \frac{\hat{\rho}_{g\{k,l\}}}{\sqrt{\hat{h}_{\{k\}}^2 \hat{h}_{\{l\}}^2}},$$

$$\hat{r}_{g\{k,l\mid x\}} = \frac{\hat{\rho}_{g\{k,l\mid x\}}}{\sqrt{\hat{h}_{\{k\mid x\}}^2 \hat{h}_{\{l\mid x\}}^2}}.$$
(2)

148

To test if the partial (or adjusted) genetic correlation estimate is different from the unadjusted geneticcorrelation estimate, the following test statistic was used:

$$t_{\{k,l\}} = \frac{\hat{r}_{g\{k,l\}} - \hat{r}_{g\{k,l\mid x\}}}{\sqrt{Var(\hat{r}_{g\{k,l\}}) + Var(\hat{r}_{g\{k,l\mid x\}}) - 2Cov(\hat{r}_{g\{k,l\}}, \hat{r}_{g\{k,l\mid x\}})}}$$
(3)

151

152 The variance of the unadjusted genetic correlation $(Var(\hat{r}_{g\{k,l\}}))$, the variance of the partial genetic 153 correlation $(Var(\hat{r}_{g\{k,l\mid x})))$ and the covariance between the two $(Cov(\hat{r}_{g\{k,l\}},\hat{r}_{g\{k,l\mid x\}})))$ were 154 obtained using a novel block-jackknife approach (see details in Supplementary Note 1). This enabled 155 us to rigorously test for a difference between the two, for the first time.

We estimated partial genetic correlations between all pairs of LTCs, using two different sets of GWAS summary statistics for BMI [21,22]. False discovery rate (FDR) correction (Q - value < 0.05) was applied for both unadjusted and partial genetic correlations, and the differences between the two, to account for multiple testing. LTC pairs were then first classified according to the difference between the two (FDR-corrected statistically significant difference or not). Significant LTC pairs were then further classified into four categories:

- Both unadjusted and partial genetic correlations were statistically non-significant (FDR of 5%);
- Both unadjusted and partial genetic correlations were statistically significant;
- Only unadjusted genetic correlations were statistically significant;
- Only partial genetic correlations were statistically significant.

Here, we focus on the results with evidence of genetic similarity before and/or after adjustment for
 BMI. LTC pairs were defined as *within-domain*, if both LTCs belong to the same disease domain, or
 cross-domain, if the two LTCs belong to different disease domains.

Our analysis pipeline has been implemented in a R package - partialLDSC - and is available on GitHub
 [https://github.com/GEMINI-multimorbidity/partialLDSC]. All analyses have been performed using
 version 0.1.0.

172 - Causal inference using Mendelian randomization

To better understand the causal relationship between BMI and each individual LTC, we performed twosample Mendelian Randomization (MR) analyses. MR is a causal inference method that uses genetic variants as instrumental variables to estimate the causal effect of an exposure on an outcome. We used it to estimate the causal effect of intervening to lower BMI on each individual LTC (Supplementary Figure 2, Supplementary Note 2).

178 Removing BMI causal effect from genetic correlations

179 For LTCs found to be strongly causally affected by BMI (23 LTCs, Supplementary Note 2), we used a 180 recently proposed Bayesian GWAS approach to derive direct effect estimates [25,26]. The direct effects 181 were estimated by taking out the causal effect of BMI from the observed association effect between 182 each genetic variant and the condition. They correspond to the direct association between genetic 183 variants and the condition, not via the BMI pathway, and can be seen as BMI-corrected GWAS summary 184 statistics. We ran the analysis for each condition using the bGWAS R-package (https://github.com/n-185 mounier/bGWAS - version 1.0.3) [25], selecting instruments for BMI using a p-value threshold of 5*10⁻ 186 ⁸ with default values used for other parameters. We then used the summary statistics for the direct 187 effects to re-estimate genetic correlations (denoted as bGWAS genetic correlations, $\hat{r}'_{a\{k,l\}}$) for 253 188 pairs. We only reported the results for the 246 pairs for which we detected a statistically significant 189 difference between the unadjusted and the partial genetic correlation estimates. We then compared 190 partial genetic correlations to bGWAS genetic correlations to understand if the difference between 191 unadjusted and partial genetic correlations are likely to be driven by the causal effect of BMI on LTCs, 192 or solely by the correlation between BMI and the LTCs, which could be due to other mechanisms.

193 Estimating the causal effect of BMI on co-occurrence of LTCs and estimating the effect of intervening194 on BMI

195 To further understand the role of BMI in the co-occurrence of LTCs, we carried out additional analyses 196 for the 15 pairs with the strongest difference, and no evidence of genetic correlation, after adjusting for BMI. First, we performed an additional GWAS in UK Biobank, defining cases for our analyses as 197 198 individuals having been diagnosed with both LTCs (Supplementary Note 3). These GWAS summary 199 statistics were then used to estimate the causal effect of BMI on the co-occurrence of each pair, using 200 the same MR approach as for individual LTCs (Supplementary Note 2). The genetic associations used 201 for MR are in standard deviation units for BMI (https://gwas.mrcieu.ac.uk/datasets/ieu-a-835/, 1SD = 202 4.77), and are log odds ratios for the outcomes. Therefore, for each pair p, the causal effect estimate 203 $\hat{\beta}_p$ represents log odds ratios per 1 standard deviation (σ) increase in the BMI on the pair, compared 204 to the actual observed BMI in the sample $(\bar{\mu})$:

$$\hat{\beta}_p = \log\left(\frac{odds \ P = 1 \ | \ BMI = \bar{\mu} + \sigma}{odds \ P = 1 \ | \ BMI = \bar{\mu}}\right) \tag{4}$$

205

This causal effect estimate can then be used to evaluate how intervening to lower BMI would affect the number of people having both LTCs [27]. In practice, for each pair, we estimated the reduction in

208 1000 individuals (\hat{R}_p) of reducing BMI by 1 SD:

$$\hat{R}_p = 1000 \cdot \left(\hat{\pi}_p - \frac{\hat{\beta}_p \, \hat{\pi}_p}{\left(1 - \hat{\pi}_p + \hat{\beta}_p \, \hat{\pi}_p \, \right)} \right),\tag{5}$$

where $\hat{\pi}_p$ is the observed prevalence for pair *p*,

- 209 using this risk reduction as the basis for further calculations. We used it to derive the number of cases
- that could be prevented from each pair following a hypothetical intervention in the sample used for
- 211 our genetic analyses and estimated the impact on the prevalence of such an intervention.

212 Results

BMI plays an important role in explaining genetic correlations between common long-term conditions.

From the 2485 pairs defined from the 71 LTCs, we detected a statistically significant difference when

adjusting for BMI genetics for 1362 pairs (Table 1, Supplementary Table 2). These pairs encompassed

217 64 out of 71 LTCs. For most of these pairs (1078/1362), the partial genetic correlation estimates were

218 weaker than the unadjusted ones, reflecting an attenuation of the genetic correlation when adjusting

- 219 for BMI genetics.
- 220 <u>Table 1</u>
- 221

	\hat{r}_g $(Q - value \ge 0.05)$	\hat{r}_g (Q - value < 0.05)
$\hat{r}_{g BMI}$ (Q - value ≥ 0.05)	308	161
$\hat{r}_{g BMI}$ $(Q - value < 0.05)$	33	860

222 Description of the 1362 pairs with statistically significant differences (Q - value < 0.05 for the test statistics 223 described in Equation 4), according to the statistical significance of unadjusted (\hat{r}_g) and partial ($\hat{r}_{g|BMI}$) genetic 224 correlation estimates.

225

In most of the pairs (860/1362) for which a statistically significant difference was observed, we found 226 227 evidence of shared genetics both before and after adjusting for BMI, indicating that while BMI 228 influences the genetic correlation for these pairs, it does not account for all of it. These include 131 229 within-domain pairs, and 769 cross-domain pairs, many of them encompassing LTCs from the "diseases 230 of the circulatory system", but also from the "diseases of the skin and subcutaneous tissue" and the 231 "diseases of the digestive system" domains. For most of these pairs, the partial genetic correlation estimates were smaller (740/860). The majority of the 120 pairs where the partial genetic correlation 232 233 estimates were larger were related to anxiety disorder (30), osteoporosis (27), schizophrenia and 234 delusional disorders (12), as well as tinnitus (11). The unadjusted and the partial genetic correlation estimates for the 20 pairs of these 860 with the strongest difference are presented in Error! Reference 235 236 source not found. Amongst these 20 top pairs, 12 distinct LTCs are represented, with some conditions 237 common between pairs with cholelithiasis in 6 pairs and carpal tunnel syndrome, gout and chronic 238 kidney disease in 7 pairs. This illustrates that BMI genetics tends to explain a larger proportion of 239 genetic correlation in pairs that contain specific LTCs. Furthermore, these LTCs are also amongst the

ones with the strongest genetic correlations with BMI (Supplementary Table 1), and most strongly
causally affected by BMI in our MR results (Supplementary Note 2). For 471 of these 860 pairs, our MR
analysis showed that BMI is likely causal for both LTCs, providing further evidence that BMI is the likely
source of the genetic correlation.

244 Figure 1



246 Unadjusted (blue circle) and partial (blue-green triangle) genetic correlation estimates and 95% confidence 247 intervals for the 20 pairs with the strongest difference (Q - value indicated for each pair on the right) and 248 evidence of shared genetics both before and after adjusting for BMI.

249

For more than 10% of the pairs with a significant difference (161/1362), we showed that BMI is likely to account for a substantial component of the genetic correlation. For these pairs, BMI adjustment resulted in a greatly reduced partial genetic correlation estimate consistent with no remaining genetic similarity between the two LTCs. Many of these pairs (76/161) included at least one condition from the *"diseases of the circulatory system"* domain, and almost all the pairs were *cross-domain* pairs (154/161)for example 24 pairs had one condition from the *"diseases of the circulatory system"* domain, and one condition from the *"diseases of the musculoskeletal system and connective tissue"* domain.

For instance, we observed complete attenuation of the genetic correlation between: type 2 diabetes and osteoarthritis $(\hat{r}_g = 0.2216 (SE = 0.0208); \hat{r}_{g|BMI} = -0.0189 (SE = 0.0296))$; gout and osteoarthritis $(\hat{r}_g = 0.1920 (SE = 0.0229); \hat{r}_{g|BMI} = 0.0191 (SE = 0.0292))$; and gout and sleep apnoea $(\hat{r}_g = 0.2313 (SE = 0.0266); \hat{r}_{g|BMI} = 0.0118 (SE = 0.0355))$ (Supplementary Table 2, <u>Figure 2</u>). For 93 of these pairs, including all the ones in Figure 2, our MR analysis detected a statistically significant causal effect of BMI on both LTCs.

263

264 <u>Figure 2</u>



266 Unadjusted (blue circle) and partial (blue-green triangle) genetic correlation estimates and 95% confidence 267 intervals for the 10 pairs with the strongest difference (Q - value indicated for each pair on the right) and 268 evidence of shared genetics only before adjusting for BMI.

269

270 For 33 LTC pairs, there was no evidence (at FDR <0.05) of genetic correlation, but on adjustment for 271 the genetics of BMI, a residual genetic effect was observed (Supplementary Table 2, Figure 3). These 272 results are consistent with BMI masking shared genetic mechanisms between the two LTCs. Most of these pairs were cross-domain pairs (28/33) and notably, 14 of these pairs were related to 273 274 osteoporosis. This can be explained by the fact that lower BMI has been shown to be associated with 275 higher osteoporosis risk [28] whereas for most other LTCs, higher BMI is suspected to be risk increasing. 276 This is further supported by our MR analysis, as we found a statistically significant causal effect of lower 277 BMI on osteoporosis (Supplementary Note 2). For 19 of these pairs, our MR results showed that BMI is likely causal for both LTCs, but protective for one of them, consistent with the partial genetic 278 correlation being stronger than the unadjusted genetic correlation. 279

280

281 Figure 3



283 Unadjusted (blue circle) and partial (blue-green triangle) genetic correlation estimates and 95% confidence 284 intervals for the 10 pairs with the strongest difference (Q - value indicated for each pair on the right) and 285 evidence of shared genetics only after adjusting for BMI.

286

For 1123 LTC pairs, adjusting for BMI genetics had no statistically significant effect on the genetic correlation between them, suggesting that other mechanisms are giving rise to the genetic similarity between these LTCs. For example, the strong genetic correlation between allergic rhinitis and bursitis $(\hat{r}_g = 0.3640 \ (SE = 0.0777); \hat{r}_{g|BMI} = 0.3639 \ (SE = 0.0795); difference Q - value = 0.98), or$ $between anxiety and schizophrenia <math>(\hat{r}_g = 0.4417 \ (SE = 0.0234); \hat{r}_{g|BMI} = 0.4414 \ (SE = 0.0232); difference Q - value = 0.91), remain similar after adjusting for BMI genetics.$

These results were consistent with those obtained using less recent BMI data, excluding UK Biobank, with partial correlation estimates that were highly similar (correlation = 0.9974, Supplementary Figure 3-A), with evidence of the analysis using the more recent data being more powered (Supplementary Table 3, Supplementary Table 4, Supplementary Figure 3-B).

297 BMI acts as a common risk factor in multimorbidity

To compare our partial genetic correlations to another method (bGWAS) we estimated pairwise genetic correlations accounting for the estimated causal effect of BMI on *both* LTCs, for 246 pairs. We studied the 23 LTCs that were strongly causally affected by BMI and a subset of LTC pairs for which a statistically significant difference between unadjusted and partial genetic correlation estimates were observed. We used bGWAS to take out the causal effect of BMI on each individual LTC and re-estimated pairwise genetic correlations. These differ from the partial correlation estimates since they only remove the BMI genetics estimated to be due to the causal role of BMI on each condition. We observed a strong agreement between the partial genetic correlation estimates and the bGWAS correlation
 estimates, with some of the bGWAS genetic correlation estimates being stronger (less attenuated) than
 the partial ones (Supplementary Error! Reference source not found.-A, Supplementary Table 5),
 suggesting that partial genetic correlation estimates might capture additional associations between
 BMI and the LTCs that are not due to these causal relationships. See Supplementary Note 4 for details.

310 For a subset of pairs, the 15 pairs with the strongest difference and no evidence of genetic correlation 311 after adjusting for BMI genetics, we performed genetic analysis for each pair and further investigated 312 the role of BMI using MR results. We showed that higher BMI had a strong risk-increasing causal effect 313 on every condition within these pairs. In addition, the unadjusted genetic correlation estimates were 314 all positive, and higher BMI was shown to be risk increasing for all LTCs (Supplementary Table 6). This 315 suggests that the attenuation of the genetic correlation is likely due to BMI acting as common risk 316 factor. This is further confirmed by the MR analysis on the pairs, with all causal effect estimates being 317 positive and statistically significant (p - value < 0.05/64, Bonferroni correction) (Supplementary 318 Table 6).

319 For these pairs with directionally consistent individual causal effects, we also estimated how 320 intervening on BMI would affect the number of people having **both** LTCs. To do so, we calculated the 321 reduction in the number of cases for 1000 individuals expected by a one SD BMI reduction. Results 322 were highly correlated with the observed prevalence of the pairs in our sample and lowering BMI had 323 a stronger effect on pairs with higher prevalence (Supplementary Table 6). Results for the 5 pairs with a prevalence above 1% are presented in Table 2. For example, 16 out of 1000 people having both 324 325 chronic kidney disease and osteoarthritis, and 9 out of 1000 people having both type 2 diabetes and 326 osteoarthritis, would not have both LTCs after a one SD BMI intervention (1SD = 4.77). In the UK 327 Biobank sample used for our analysis, this would translate into a 4.6% reduction in prevalence for the 328 co-occurrence of chronic kidney disease and osteoarthritis, and 3.3% reduction in prevalence for the 329 co-occurrence of type 2 diabetes and osteoarthritis. We postulate that the impact of such an 330 intervention in the general population is likely to be stronger, since the prevalence of these pairs of 331 LTC in UK Biobank is lower than in the general population (Supplementary Table 6), due to healthy 332 volunteer bias in UK Biobank [29].

333

334 <u>Table 2</u>

335

condition 1	condition 2	\hat{r}_{g} (SE)	$\hat{r}_{g BMI}$ (SE)	\hat{eta}_{IVW} (SE ; $p-value$)	Ŕ	π UK Biobank	$\widehat{\pi}_{\scriptscriptstyle R}$ UK Biobank
Chronic Kidney Disease	Osteoarthritis	0.1356 (0.0330)	0.0202 (0.0359)	0.38 (0.0835 ; 4.2e-06)	16.76	2.752	2.706
Diabetes Type 2	Osteoarthritis	0.2216 (0.0208)	-0.0189 (0.0296)	0.71 (0.1820 ; 9.4e-05)	9.69	3.434	3.401
Cholelithiasis	Osteoarthritis	0.2110 (0.0295)	0.0538 (0.0323)	0.63 (0.0775 ; 6.0e-16)	8.83	2.406	2.385
Asthma	Chronic Kidney Disease	0.0829 (0.0353)	0.0158 (0.0361)	0.35 (0.1132 ; 2.1e-03)	7.10	1.092	1.085
Gout	Osteoarthritis	0.1920 (0.0229)	0.0191 (0.0292)	0.61 (0.0963 ; 3.2e-10)	6.47	1.657	1.646

336 Mendelian randomization and BMI intervention results for 5 pairs with a prevalence above 1% in our sample.

337 For each pair of LTC (condition 1 and condition 2), the unadjusted genetic correlation estimate and standard

error (\hat{r}_g) , the partial genetic correlation estimate and standard error $(\hat{r}_{g|BMI})$, as well as the causal effect

estimate ($\hat{\beta}_{IVW}$), its standard error and the corresponding p-value, of BMI on the pair, and the reduction in the

number of cases with both LTCs when reducing BMI by one SD for 1000 individuals (\hat{R}), and the prevalence of

341 cases with both LTCs in percentage in UK Biobank before (π UK Biobank) and after an hypothetical intervention

342 ($\hat{\pi}_R$ UK Biobank), are reported.

343

344 Discussion

345 Clinical trials and Mendelian randomization studies have shown that obesity is very likely to cause 346 many individual LTCs [30]. However, the role of higher BMI in the co-occurrence of two LTCs and the 347 extent to which it accounts for some, or all of the co-occurrence is less certain. In this study we 348 combined genetics data from very large studies with a novel statistical analysis technique to estimate 349 the extent to which higher BMI influences the genetic similarity between pairs of LTCs. Our analyses 350 indicated that for a large proportion of pairs of LTCs, higher BMI is likely to explain part of the genetic 351 correlation, but that other factors are likely to also contribute. For 55% of LTC-pairs tested we observed 352 a change in the genetic correlations when accounting for BMI genetics. Using causal inference 353 methods, we confirmed that BMI acts as a common risk factor for a subset of these pairs, and that 354 intervening on BMI could help reduce the prevalence of pairs of multimorbid LTCs.

355 Our analyses indicated that for 36% (740/2485) of LTCs pairs we studied, higher BMI could explain a significant proportion of their genetic correlation. Of these, 161 pairs were identified for which the 356 estimates were consistent with a null partial genetic correlation, suggesting that the genetic similarity 357 358 between these pairs of LTCs is *entirely* explained by the BMI. These included many pairs that spanned 359 traditional disease domains, especially those involving osteoarthritis and metabolic diseases, and 360 COPD and metabolic diseases. For some of these pairs, previous studies have observed a similar strong attenuating effect of BMI, such as for type 2 diabetes and osteoarthritis and gout and sleep apnoea 361 362 [31,32].

363 Thirty-three pairs (about 1%) of LTCs showed no evidence of unadjusted genetic similarity, but after 364 accounting for the genetic effect of BMI, a partial genetic correlation emerged. These results suggest 365 that shared genetic causes may exist for some pairs, but they could be masked by BMI having effects 366 in opposite directions. Most of these pairs were related to osteoporosis, which may be explained by 367 the fact that the direction of the effect of BMI on osteoporosis is opposite to the one on most other LTCs [33]. We observed for example a positive genetic correlation between osteoporosis and stroke, 368 only after accounting for BMI genetics. Because genetic risk usually reflects life-long exposure, this 369 370 correlation suggests the presence of shared risk factors for osteoporosis and metabolic traits, although 371 we cannot rule out a genetic correlation resulting from reduced mobility and bone load reduction in 372 stroke patients [34].

Our results corroborate the role of BMI acting as a common risk factor for various pairs of LTCs. We have used causal inference approaches to test the causal relationship between BMI and the different LTCs, and we used the bGWAS approach to re-estimate genetic correlation estimates, adjusting only 376 for the part of the genetic correlation that is driven by the causal effect of BMI on the LTCs. Overall, we 377 observed a strong agreement between partial and bGWAS genetic correlation estimates, providing 378 further evidence that BMI does act as common risk factor. However, the bGWAS genetic correlation 379 estimates were in general stronger, suggesting that the correlation between BMI and the LTCs is not 380 entirely explained by the causal effect and that more complex relationships may exist. In addition, the 381 effects derived from bGWAS would only capture linear causal effects, so any non-linear effects would not be accounted for, possibly explaining why the bGWAS genetic correlations estimates were stronger. 382 383 We also showed that BMI has a strong, risk-increasing, causal effect on some pairs of LTCs, and that 384 lowering BMI could help reduce the prevalence of these pairs.

Many of the LTC pairs include those from across traditional clinical domains, and for a majority of these 385 386 pairs, the attenuation after accounting for BMI was as strong as that for within-domain pairs. For 387 example, based on our genetic approach, the role of BMI in explaining the co-occurrence of COPD and 388 several metabolic LTCs and osteoarthritis and several metabolic LTCs, is just as strong as the role of 389 BMI in explaining the co-occurrence of two metabolic LTCs. The reasons for these findings require 390 further investigation but our results suggest that interventions aimed at weight loss should monitor 391 these additional LTCs more closely, or conversely, patients with a combination of obesity and a 392 metabolic condition should be monitored for less obvious non-metabolic LTCs.

393 The definition of obesity, and other obesity-related measures and phenotypes that can be used as 394 proxies in public health research, is critical [35] and which one is the best predictor for disease risk 395 might depend on the condition [36–42]. For that reason, we believe that results using BMI, as a 396 continuous phenotype that can be easily measured in the general population, are less likely to be 397 biased and are easier to interpret. Further analyses, to better understand how exactly BMI affects each 398 condition could be performed, using clustering-based MR approaches for instance [43]. Other obesity-399 related phenotypes should be used to investigate the effect of body fat distribution, like waist-to-hip 400 ratio for example, and these analyses would benefit from a sex-specific approach, to better account 401 for the known sex-specific genetic architecture of such phenotypes [44,45].

This work focused on individuals of European descent, mostly because of data availability, and analyses are needed in other ethnic groups, as it is known that both BMI distribution [46] and its effect on LTCs may vary depending on ethnicity [47,48], to further understand the role of BMI in multimorbidity in these groups. It is important to note that the relative paucity of data from people of non-European ancestry has a disproportionately large effect on the utility of genetics for multimorbidity, because missing data from only one condition will affect multiple pairs.

408 This work not only has important implications for research that aims at identifying shared biological 409 pathways between pairs of LTCs but also has direct implications for potential intervention. We showed 410 that intervening on BMI would directly impact the prevalence of pairs of LTCs, such as type 2 diabetes 411 and chronic kidney disease, or type 2 diabetes and osteoarthritis. This is particularly important with 412 the recent commercialisation of weight loss drugs that could be used to reduce the co-occurrence of 413 LTCs through a better weight management strategy. This work focused on individuals of European 414 descent, mostly because of data availability, and analyses are needed in other ethnic groups, as it is known that both BMI distribution [46] and its effect on LTCs may vary depending on ethnicity [47,48], 415 416 to further understand the role of BMI in multimorbidity in these groups. 417 418

- 419
- 420

421 Funding

This work was supported by the UK Medical Research Council [grant number MR/W014548/1]. This study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre (BRC), the NIHR Leicester BRC, the NIHR Oxford BRC, the NIHR Peninsula Applied Research Collaboration, and the NIHR Health Tech Research Centre. JM is funded by an NIHR Advanced Fellowship (NIHR302270). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

428 Acknowledgements

We acknowledge all members of the GEMINI Consortium. This includes researchers Olivia Murrin, Carlos Gallego-Moll, Albert Roso-Llorach, Lucía A Carrasco-Ribelles, Chris Fox, Louise M Allan, Xiaoran Liang, Ruby M Woodward, Deniz Türkmen, Kate Boddy, Jose M Valderas, Sara M Khalid, Sally E Lamb, David Melzer, and Concepción Violán, in addition to patient representatives Mary Mancini and Leon Farmer. The whole GEMINI team were central to developing the LTC definitions, observational associations in population representative primary care cohorts, genetic associations between LTC pairs, and developing and refining the research question(s) and results.

This research has been conducted using the UK Biobank Resource under Application Number 9072. We want to acknowledge the participants and investigators of the FinnGen study. We also thank the authors and study participants for the published GWAS consortium meta-analyses utilized in this report (see [11] and the project GitHub pages [https://github.com/GEMINI-multimorbidity] for details and citation). The authors would like to acknowledge the use of the University of Exeter High-Performance Computing (HPC) facility in carrying out this work.

442 Disclosures

JB is a part time employee of Novo Nordisk Research Centre Oxford, limited. TF has consulted for
 several pharmaceutical companies. All other authors have no disclosures to declare.

445 Contributions

- 446 Conceptualization: NM, LP, FD, TF, JB. Data Curation NM, BV, LP: Formal Analysis: NM, BV, LP. Funding
- 447 Acquisition JM, JD, FD, LP, JB, TF. Interpretation: NM, BV, JM, JD, FD, LP, TF, JB. Investigation: NM, JB.
- 448 Resources: NM, BV, LP. Software: NM Supervision: JB, TF, LP, FD. Writing Original Draft: Writing NM,
- 449 LP, TF, JB. Review & Editing: NM, BV, JM, JD, FD, LP, TF, JB.
- 450

451 References

- Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with
 multimorbidity: A systematic review of the literature. Ageing Res Rev. 2011;10: 430–439.
 doi:10.1016/j.arr.2011.03.003
- Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring
 multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019;29: 182–
 189. doi:10.1093/eurpub/cky098
- 458 3. Ho ISS, Azcoaga-Lorenzo A, Akbari A, Davies J, Khunti K, Kadam UT, et al. Measuring
 459 multimorbidity in research: Delphi consensus study. BMJ medicine. 2022;1: e000247.
 460 doi:10.1136/bmjmed-2022-000247
- 461 4. Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence
 462 of multimorbidity in the adult population in community settings: a systematic review and
 463 meta-analysis. EClinicalMedicine. 2023;57: 101860. doi:10.1016/j.eclinm.2023.101860
- 464 5. Calderón-Larrañaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfí A,
 465 et al. Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for
 466 Its Operationalization. J Gerontol A Biol Sci Med Sci. 2017;72: 1417–1423.
 467 doi:10.1093/gerona/glw233
- Zemedikun DT, Gray LJ, Khunti K, Davies MJ, Dhalwani NN. Patterns of Multimorbidity in
 Middle-Aged and Older Adults: An Analysis of the UK Biobank Data. Mayo Clin Proc. 2018;93:
 857–866. doi:10.1016/j.mayocp.2018.02.012
- 471 7. Ho IS-S, Azcoaga-Lorenzo A, Akbari A, Black C, Davies J, Hodgins P, et al. Examining variation in
 472 the measurement of multimorbidity in research: a systematic review of 566 studies. Lancet
 473 Public Health. 2021;6: e587–e597. doi:10.1016/S2468-2667(21)00107-9
- Nichols L, Taverner T, Crowe F, Richardson S, Yau C, Kiddle S, et al. In simulated data and
 health records, latent class analysis was the optimum multimorbidity clustering algorithm. J
 Clin Epidemiol. 2022;152: 164–175. doi:10.1016/j.jclinepi.2022.10.011
- Pathirana TI, Jackson CA. Socioeconomic status and multimorbidity: a systematic review and
 meta-analysis. Aust N Z J Public Health. 2018;42: 186–194. doi:10.1111/1753-6405.12762
- 479 10. Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, et al. Body-mass index and
 480 risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet
 481 Diabetes Endocrinol. 2022;10: 253–263. doi:10.1016/S2213-8587(22)00033-X
- 482 11. Murrin O, Mounier N, Voller B, Tata L, Gallego-Moll C, Roso-Llorach A, et al. A systematic
 483 analysis of the contribution of genetics to multimorbidity and comparisons with primary care
 484 data. medRxiv. 2024; 2024.05.13.24307009. doi:10.1101/2024.05.13.24307009
- Kraft P, Chen H, Lindström S. The Use Of Genetic Correlation And Mendelian Randomization
 Studies To Increase Our Understanding of Relationships Between Complex Traits. Curr
 Epidemiol Rep. 2020;7: 104–112. doi:10.1007/s40471-020-00233-6
- 13. Dixon P, Hollingworth W, Harrison S, Davies NM, Davey Smith G. Mendelian Randomization
 analysis of the causal effect of adiposity on hospital costs. J Health Econ. 2020;70: 102300.
 doi:10.1016/j.jhealeco.2020.102300

- 491 14. van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR. Genetic correlations of polygenic
 492 disease traits: from theory to practice. Nat Rev Genet. 2019;20: 567–581.
 493 doi:10.1038/s41576-019-0137-z
- 494 15. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal
 495 relationships inferred from Mendelian randomization between complex traits and diseases.
 496 Nat Genet. 2018;50: 693–698. doi:10.1038/s41588-018-0099-7
- Larsson SC, Burgess S. Causal role of high body mass index in multiple chronic diseases: a
 systematic review and meta-analysis of Mendelian randomization studies. BMC Med.
 2021;19: 320. doi:10.1186/s12916-021-02188-x
- 50017.World Health Organisation. International Statistical Classification of Diseases and Related501Health Problems (ICD). 2019 [cited 1 Jul 2022]. Available: https://icd.who.int/
- Recalde M, Rodríguez C, Burn E, Far M, García D, Carrere-Molina J, et al. Data Resource
 Profile: The Information System for Research in Primary Care (SIDIAP). Int J Epidemiol.
 2022;51: e324–e336. doi:10.1093/ije/dyac068
- Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data Resource
 Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44: 827–836.
 doi:10.1093/ije/dyv098
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access
 Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old
 Age. PLoS Med. 2015;12: e1001779. doi:10.1371/journal.pmed.1001779
- S11 21. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of
 genome-wide association studies for height and body mass index in ~700000 individuals of
 European ancestry. Hum Mol Genet. 2018;27: 3641–3649. doi:10.1093/hmg/ddy271
- Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass
 index yield new insights for obesity biology. Nature. 2015;518: 197–206.
 doi:10.1038/nature14177
- 517 23. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression
 518 distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet.
 519 2015;47: 291–295. doi:10.1038/ng.3211
- 520 24. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, et al. An atlas of genetic
 521 correlations across human diseases and traits. Nat Genet. 2015;47: 1236–41.
 522 doi:10.1038/ng.3406
- 52325.Mounier N, Kutalik Z. bGWAS: an R package to perform Bayesian genome wide association524studies. Bioinformatics. 2020;36: 4374–4376. doi:10.1093/bioinformatics/btaa549
- Pirastu N, McDonnell C, Grzeszkowiak EJ, Mounier N, Imamura F, Merino J, et al. Using genetic
 variation to disentangle the complex relationship between food intake and health outcomes.
 PLoS Genet. 2022;18: e1010162. doi:10.1371/journal.pgen.1010162
- 52827.Murad MH, Wang Z, Zhu Y, Saadi S, Chu H, Lin L. Methods for deriving risk difference (absolute529risk reduction) from a meta-analysis. BMJ. 2023; e073141. doi:10.1136/bmj-2022-073141

- 530 28. Espallargues M, Sampietro-Colom L, Estrada MD, Solà M, del Río L, Setoain J, et al. Identifying
 531 Bone-Mass-Related Risk Factors for Fracture to Guide Bone Densitometry Measurements: A
 532 Systematic Review of the Literature. Osteoporosis International. 2001;12: 811–822.
 533 doi:10.1007/s001980170031
- 534 29. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
 535 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those
 536 of the General Population. Am J Epidemiol. 2017;186: 1026–1034. doi:10.1093/aje/kwx246
- 53730.Kivimäki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M, et al. Body-mass index and538risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet539Diabetes Endocrinol. 2022;10: 253–263. doi:10.1016/S2213-8587(22)00033-X
- 54031.Duclos M. Osteoarthritis, obesity and type 2 diabetes: The weight of waist circumference. Ann541Phys Rehabil Med. 2016;59: 157–160. doi:10.1016/j.rehab.2016.04.002
- 32. Zeng Z, Jin T, Ni J, Huang L, Xie Y, He W, et al. Assessing the causal associations of obstructive
 sleep apnea with serum uric acid levels and gout: a bidirectional two-sample Mendelian
 randomization study. Semin Arthritis Rheum. 2022;57: 152095.
 doi:10.1016/j.semarthrit.2022.152095
- 546 33. Espallargues M, Sampietro-Colom L, Estrada MD, Solà M, del Río L, Setoain J, et al. Identifying
 547 Bone-Mass-Related Risk Factors for Fracture to Guide Bone Densitometry Measurements: A
 548 Systematic Review of the Literature. Osteoporosis International. 2001;12: 811–822.
 549 doi:10.1007/s001980170031
- S4. Carda S, Cisari C, Invernizzi M, Bevilacqua M. Osteoporosis after Stroke: A Review of the
 Causes and Potential Treatments. Cerebrovascular Diseases. 2009;28: 191–200.
 doi:10.1159/000226578
- 55335.Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92: 6–10.554doi:10.1016/j.metabol.2018.09.005
- 55536.Sulc J, Winkler TW, Heid IM, Kutalik Z. Heterogeneity in Obesity: Genetic Basis and Metabolic556Consequences. Curr Diab Rep. 2020;20: 1. doi:10.1007/s11892-020-1285-4
- Sulc J, Sonrel A, Mounier N, Auwerx C, Marouli E, Darrous L, et al. Composite trait Mendelian
 randomization reveals distinct metabolic and lifestyle consequences of differences in body
 shape. Commun Biol. 2021;4: 1064. doi:10.1038/s42003-021-02550-y
- 38. Martin S, Tyrrell J, Thomas EL, Bown MJ, Wood AR, Beaumont RN, et al. Disease
 consequences of higher adiposity uncoupled from its adverse metabolic effects using
 Mendelian randomisation. Elife. 2022;11. doi:10.7554/eLife.72452
- 563 39. Emerenziani S, Pier Luca Guarino M, Trillo Asensio L, Altomare A, Ribolsi M, Balestrieri P, et al.
 564 Role of Overweight and Obesity in Gastrointestinal Disease. Nutrients. 2019;12: 111.
 565 doi:10.3390/nu12010111
- 566 40. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:
 565–574. doi:10.1016/S1470-2045(02)00849-5
- 568 41. Silva Junior GB da, Bentes ACSN, Daher EDF, Matos SMA de. Obesity and kidney disease.
 569 Jornal Brasileiro de Nefrologia. 2017;39. doi:10.5935/0101-2800.20170011

Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss
and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23: 1499–
1504. doi:10.2337/diacare.23.10.1499

- Liang X, Mounier N, Apfel N, Khalid S, Frayling TM, Bowden J, et al. Using clustering of genetic
 variants in Mendelian randomization to interrogate the causal pathways underlying
 multimorbidity. medRxiv. 2023; 2023.03.18.23287164. doi:10.1101/2023.03.18.23287164
- 44. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of
 genome-wide association studies for body fat distribution in 694 649 individuals of European
 ancestry. Hum Mol Genet. 2019;28: 166–174. doi:10.1093/hmg/ddy327
- 579 45. Censin JC, Peters SAE, Bovijn J, Ferreira T, Pulit SL, Mägi R, et al. Causal relationships between
 580 obesity and the leading causes of death in women and men. PLoS Genet. 2019;15: e1008405.
 581 doi:10.1371/journal.pgen.1008405
- 46. Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM. Why are there race/ethnic
 differences in adult body mass index–adiposity relationships? A quantitative critical review.
 Obesity Reviews. 2016;17: 262–275. doi:10.1111/obr.12358
- 58547.Colin Bell A. Ethnic Differences in the Association between Body Mass Index and586Hypertension. Am J Epidemiol. 2002;155: 346–353. doi:10.1093/aje/155.4.346
- 587 48. Caleyachetty R, Barber TM, Mohammed NI, Cappuccio FP, Hardy R, Mathur R, et al. Ethnicity588 specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based
 589 cohort study. Lancet Diabetes Endocrinol. 2021;9: 419–426. doi:10.1016/S2213590 8587(21)00088-7
- 591

592